Adalimumab, Infliximab And Etanercept Biosimilars Global Market Opportunities And Strategies To 2031

Adalimumab, Infliximab And Etanercept Biosimilars Market 2022 – By Product (Adalimumab Biosimilars, Infliximab Biosimilars, Cipleumab), By Application (Crohn’s Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Other Applications), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And By Region, Opportunities And Strategies – Global Forecast To 2031

Name: Adalimumab, Infliximab And Etanercept Biosimilars Global Market Opportunities And Strategies To 2031
Creator: The Business Research Company
License: https://www.thebusinessresearchcompany.com/privacy-policy

Adalimumab, Infliximab And Etanercept Biosimilars Global Market Opportunities And Strategies To 2031

Starting Price : $5000.00 $3500.00 | Pages : 252 | Published : October 2022 | | Format : pdf

Purchase Options

Request a Sample

Request For Discount

Customise Your Report

Item added to cart!

Request For Proposal

Request For Regional Data

Need assistance or more information before the purchase?

Enquire Before Buying

Proud Members Of

Adalimumab, Infliximab And Etanercept Biosimilars Market Definition

The adalimumab, infliximab and etanercept biosimilars market consists of sales of adalimumab, infliximab and etanercept biosimilar drugs by the companies that manufacture these biosimilars. Adalimumab, infliximab and etanercept biosimilar molecules are bioequivalent to original reference molecules namely Humira, Remicade and Enbrel, respectively.

Book your 30 minutes free consultation with our research experts

Adalimumab, Infliximab And Etanercept Biosimilars Market Size

The global adalimumab, infliximab and etanercept biosimilars market size reached a value of nearly $2,757.45 million in 2021, having grown at a compound annual growth rate (CAGR) of 93.90% since 2016. The global adalimumab, infliximab and etanercept biosimilars market size is expected to grow from $2,757.45 million in 2021 to $5,591.82 million in 2026 at a rate of 15.20%. The global adalimumab, infliximab and etanercept biosimilars market size is then expected to grow at a CAGR of 9.96% from 2026 and reach $8,991.32 million in 2031.

Growth in the historic period resulted from increased healthcare expenditure, regulatory changes, regulatory changes, government initiatives and rising healthcare costs. The market was restrained by the companies gaining market share without a simple price war, low healthcare access and a lack of awareness on biosimilars among primary care physicians and specialists.

Going forward, a rise in healthcare expenditure, aging population and an increase in healthcare access will drive dalimumab, infliximab and etanercept biosimilars market growth. Factors that could hinder the growth of the adalimumab, infliximab and etanercept biosimilars market in the future include insufficient and outdated health system infrastructure.

Adalimumab, Infliximab And Etanercept Biosimilars Market Drivers

The key drivers of the adalimumab, infliximab and etanercept biosimilars market include:

Rise In Healthcare Expenditure

Increasing healthcare expenditure is also rising in healthcare costs that is predicted to increase the demand for the adalimumab, infliximab and etanercept biosimilars market if the cost of biosimilar is reduced.

According to the National Health Expenditure Projections 2018-2027, by 2027 the national healthcare expenditure in the USA is expected to reach nearly $6.0 trillion, which is growing at an average rate of 5.5% annually from 2018 to 2027. Annually, Prescription drug spending is projected to grow by 6.1% during 2020-2027. Consequently, the rise in healthcare spending is to increase the market for adalimumab, infliximab and etanercept biosimilars in the near future.

Adalimumab, Infliximab And Etanercept Biosimilars Market Restraints

The key restraints on the adalimumab, infliximab and etanercept biosimilars market include:

Insufficient And Outdated Health System

Insufficient and outdated health system infrastructure (facilities, technology, clinicians) remains, for many, a major hurdle to achieving health equity.

Fewer than 50% of Africans have access to modern health facilities. Further, around 61% of births were attended by skilled health staff in 2018, far fewer than the 80% global average. And although more people in India’s smaller towns and rural areas now have money for health care through the new PMSBY insurance scheme, they have limited options to use it because clinician and product supply is limited, and government health facilities are few and far between.

As of 2019, 9.6% of the 24,855 primary health centers (PHCs) in India had no doctor, 38.4% had no laboratory technician, and 23.9% had no pharmacist. There are also severe gaps in skilled professionals: For rural community health centers in 2019, only 15% of the surgical posts, 13% of the physician posts, 25% of the obstetrics and gynecology posts, and 20% of the pediatrician posts were filled.

Adalimumab, Infliximab And Etanercept Biosimilars Market Trends

Major trends influencing the adalimumab, infliximab and etanercept biosimilars market include:

Robust Competition in the Marketplace

Biosimilars are being launched in new territories and geographies. For example, in February 2021, Viatris Inc., American global healthcare company, launched Hulio (Adalimumab Biosimilar) in Canada. This launch has increased patient access resulting in better health, by providing Canadian patients with chronic inflammatory disorders with an additional treatment option.

Also, in February 2021 Sandoz Canada, launched Hyrimoz (adalimumab biosimilar injection). Sandoz is maximizing the value of Hyrimoz by maximizing approved indications to nine of the twelve serious debilitating or life-threatening conditions in adults and children treated by the reference medicine.

The demand for agents to treat autoimmune disease such as Crohn’s disease, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, ankylosing spondylitis, plaque psoriasis has been increasing. Due to the high cost of originator biologicals the EMA and the FDA have each granted license to a number of TNFa biosimilars to increase competition and drive costs down.

For example, by the end of 2023, seven or more Humira biosimilar competitors are expected to launch in the US. Humira has undergone numerous changes over the period such as, new concentrations, citrate-free variations, latex-free delivery methods, and smaller needle gauges as part of AbbVie’s strategy to protect their franchise. The biosimilar companies will have to compete aggressively in the market place to capture market share from Humira. With an average monthly treatment cost of $6,000 for Humira, much of this competition will be based on price.

Growing Mergers And Acquisitions

The focus areas for many companies in the adalimumab, infliximab and etanercept biosimilars market have shifted to increasing mergers and acquisitions to acquire more production capabilities. Large prime manufacturers are forming joint ventures or buying small or midsized companies to acquire new capabilities or gain access to new markets.

For example, in February 2022, Biocon Biologics, India based biopharmaceutical company (a subsidiary of Biocon Ltd.), acquired Viatris’ Biosimilars for a deal value of $3.3 billion. Viatris is a US-based pharmaceutical company.

Also, in November 2019, Biogen Inc, a US-based multinational biotechnology company based in Cambridge, Massachusetts, acquired Samsung Bioepis Co., Ltd. to get the exclusive powers to market two new ophthalmology biosimilars, SB11 referencing Lucentis 1 and SB15 referencing Eylea 2, in major markets globally, including the U.S., Canada, Europe, Japan, and Australia. Samsung Bioepis is a biopharmaceutical company. It produces biosimilars medicines and other related products.

Opportunities And Recommendations In The Adalimumab, Infliximab And Etanercept Biosimilars Market

Opportunities –The top opportunities in the adalimumab, infliximab and etanercept biosimilars market segmented by product will arise in the adalimumab biosimilars market segment, which will gain $1,165.5 million of global annual sales by 2026. The top opportunities in the adalimumab, infliximab and etanercept biosimilars market segmented by application will arise in the other applications market segment, which will gain $ 601.4 of global annual sales by 2026. The top opportunities in the adalimumab, infliximab and etanercept biosimilars market segmented by distribution channel will arise in the hospital pharmacies market segment, which will gain $1,939.2 of global annual sales by 2026. The global adalimumab, infliximab and etanercept biosimilars market size will gain the most in the USA at $738.0 million.

Recommendations –To take advantage of the opportunities, The Business Research Company recommends the adalimumab, infliximab and etanercept biosimilars companies to focus on new product launches, expand in emerging markets, increase focus on mergers and acquisitions, offer competitive pricing, continue to participate in events and conferences and focus on fast-growing applications.

Adalimumab, Infliximab And Etanercept Biosimilars Market Segmentation

The adalimumab, infliximab and etanercept biosimilars market is segmented by product, by application, and by distribution channel.
By Product –
The adalimumab, infliximab and etanercept biosimilars market is segmented by product into

a) Adalimumab Biosimilars
b) Infliximab Biosimilars
c) Cipleumab

The adalimumab, infliximab and etanercept biosimilars market was the largest segment of the adalimumab, infliximab and etanercept biosimilars market segmented by product, accounting for 39.33% of the total in 2021. Going forward, the Cipleumab segment is expected to be the fastest growing segment in the adalimumab, infliximab and etanercept biosimilars market segmented by product, at a CAGR of 17.18% during 2021-2026.
By Application–
The adalimumab, infliximab and etanercept biosimilars market is segmented by application into

a) Crohn’s Disease
b) Psoriatic Arthritis
c) Rheumatoid Arthritis
d) Ulcerative Colitis
e) Ankylosing Spondylitis
f) Plaque Psoriasis
g) Other Applications

The other applications market was the largest segment of the adalimumab, infliximab and etanercept biosimilars market segmented by application, accounting for 20.1% of the total in 2021. Going forward, the other applications segment is expected to be the fastest growing segment in the adalimumab, infliximab and etanercept biosimilars market segmented by application, at a CAGR of 15.8% during 2021-2026.
By Distribution Channel –
The adalimumab, infliximab and etanercept biosimilars market is segmented by distribution channel into

a) Hospital Pharmacies
b) Retail Pharmacies
c) Online Pharmacies

The hospital pharmacies market was the largest segment of the adalimumab, infliximab and etanercept biosimilars market segmented by distribution channel, accounting for 87.7% of the total in 2021. Going forward, the online pharmacies segment is expected to be the fastest growing segment in the adalimumab, infliximab and etanercept biosimilars market segmented by distribution channel, at a CAGR of 32.2% during 2021-2026.
By Geography- The adalimumab, infliximab and etanercept biosimilars market is segmented by geography into

o Asia Pacific
- • China
- • Japan
- • India
- • Australia
- • Indonesia
- • South Korea

• USA

• Brazil

• UK
• Germany
• France

• Russia

Western Europe was the largest region in the global adalimumab, infliximab and etanercept biosimilars market, accounting for 86.3% of the total in 2021. It was followed by North America, and then the other regions. Going forward, the fastest-growing regions in the global adalimumab, infliximab and etanercept biosimilars market will be Africa, and, Eastern Europe where growth will be at CAGRs of 110.4% and 56.5% respectively. These will be followed by Middle East, and, South America where the markets are expected to grow at CAGRs of 52.9% and 50.3% respectively.

Adalimumab, Infliximab And Etanercept Biosimilars Market Competitive Landscape

Major Competitors are:

Biogen

Novartis (Sandoz)

Pfizer

Amgen

Celltrion

Other Competitors Include:

Samsung Bioepis (Samsung Biologics)

Hetero Drugs Limited

Fresenius Kabi AG

Boehringer Ingelheim

Biocon

Zydus Lifesciences Limited

Reliance Life Sciences

Torrent Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd

Cipla Limited

Zhejiang Hisun Pharmaceutical Co. Ltd

Bio- Thera Solutions, Ltd

Innovent Biologics (Suzhou) Co. Ltd

Janssen Biologics BV

Shanghai CP Guojian Pharmaceutical Co. Ltd

Sansheng Guojian

Shanghai Junshi Biosciences Co. Ltd

Mabwell Bioscience Co. Ltd

LG Chem

Nippon Kayaku

Mochida Pharmaceutical Co. Ltd

mAbxience

Allergan

Microgen

Geropharm

Valenta

NovaMedica Veropharm

Biocad

Roche

Bristol-Myers Squibb

Celon Pharma

SynBio

Celgene Corporation

AstraZeneca

Merck & Co

Gilead Sciences

Regeneron Pharmaceuticals

Rani Therapeutics

Eli Lilly and Company

Emisphere Technologies Inc

Enteris BioPharma

Allena Pharmaceuticals

Abbvie

Johnson & Johnson

Ache

Eurofarma

Sanofi

Teva Pharmaceuticals

Oramed Pharmaceuticals

Entera Bio

Julphar

Hikma Pharmaceuticals

Mylan

BIOPHARMA-MEA

NeoTX

AID Genomics Limited

Altis Biologics

Cipla Medpro South Africa

Sanofi Genzyme

Next Biosciences

Viome

Inqaba Biotechnical Industries (Pty) Ltd

1. Adalimumab, Infliximab And Etanercept Biosimilars Market Executive Summary

2. Table of Contents

3. List of Figures

4. List of Tables

5. Report Structure

6. Introduction and Market Characteristics

6.1. General Market Definition

6.2. Summary

6.3. Adalimumab, Infliximab And Etanercept Biosimilars Market Definition and Segmentations

6.4. Market Segmentation By Product

6.4.1. Adalimumab Biosimilars

6.4.2. Infliximab Biosimilars

6.4.3. Etanercept Biosimilars

6.5. Market Segmentation By Application

6.5.1. Crohn’s Disease

6.5.2. Psoriatic Arthritis

6.5.3. Rheumatoid Arthritis

6.5.4. Ulcerative Colitis

6.5.5. Ankylosing Spondylitis

6.5.6. Plaque Psoriasis

6.5.7. Other Applications

6.6. Market Segmentation By Distribution Channel

6.6.1. Hospital Pharmacies

6.6.2. Retail Pharmacies

6.6.3. Online Pharmacies

7. Major Market Trends

7.1. Robust Competition in the Marketplace

7.2. Growing Mergers And Acquisitions

7.3. Revised FDA Regulations To Facilitate Biosimilar Drug Development

7.4. Large Number Of Strategic Partnerships

7.5. Increasing Investments In Biosimilars Market

8. Global Market Size And Growth

8.1. Market Size

8.2. Historic Market Growth, 2016 – 2021, Value ($ Million)

8.2.1. Market Drivers 2016 – 2021

8.2.2. Market Restraints 2016 – 2021

8.3. Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

8.3.1. Market Drivers 2021 – 2026

8.3.2. Market Restraints 2021 – 2026

9. Adalimumab, Infliximab and Etanercept Biosimilars Market, Regional Analysis

9.1. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, By Region, Historic and Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

9.2. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, By Country, Historic and Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

10. Global Adalimumab, Infliximab and Etanercept Biosimilars Market Segmentation

10.1. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

10.2. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

10.3. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distributional Channel, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

11. Asia-Pacific Market

11.1. Summary

11.2. Asia Pacific Market Overview

11.2.1. Region Information

11.2.2. Market Information

11.2.3. Background Information

11.2.4. Government Initiatives

11.2.5. Regulations

11.2.6. Regulatory Bodies

11.2.7. Major Associations

11.2.8. Taxes Levied

11.2.9. Corporate Tax Structure

11.2.10. Investments

11.2.11. Major Companies

11.3. Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

11.4. Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

11.5. Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

11.6. Asia Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market: Country Analysis

11.7. China Market

11.8. Summary

11.9. China Market Overview

11.9.1. Country Information

11.9.2. Market Information

11.9.3. Background Information

11.9.4. Government Initiatives

11.9.5. Regulations

11.9.6. Regulatory Bodies

11.9.7. Major Associations

11.9.8. Taxes Levied

11.9.9. Corporate Tax Structure

11.9.10. Investments

11.9.11. Major Companies

11.10. China Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

11.11. China Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

11.12. China Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

11.13. India Market

11.14. India Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

11.15. India Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

11.16. India Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

11.17. Japan Market

11.18. Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

11.19. Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

11.20. Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

11.21. Australia Market

11.22. Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

11.23. Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

11.24. Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

11.25. Indonesia Market

11.26. Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

11.27. Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

11.28. Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

11.29. South Korea Market

11.30. South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

11.31. South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

11.32. South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

12. Western Europe Market

12.1. Summary

12.2. Western Europe Market Overview

12.2.1. Region Information

12.2.2. Market Information

12.2.3. Background Information

12.2.4. Government Initiatives

12.2.5. Regulations

12.2.6. Regulatory bodies

12.2.7. Major Associations

12.2.8. Taxes Levied

12.2.9. Corporate Tax Structure

12.2.10. Investments

12.2.11. Major Companies

12.3. Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

12.4. Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

12.5. Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

12.6. Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market: Country Analysis

12.7. UK Market

12.8. UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

12.9. UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

12.10. UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

12.11. Germany Market

12.12. Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

12.13. Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

12.14. Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

12.15. France Market

12.16. France Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

12.17. France Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

12.18. France Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

13. Eastern Europe Market

13.1. Summary

13.2. Eastern Europe Market Overview

13.2.1. Region Information

13.2.2. Market Information

13.2.3. Background Information

13.2.4. Government Initiatives

13.2.5. Regulations

13.2.6. Regulatory Bodies

13.2.7. Major Associations

13.2.8. Taxes Levied

13.2.9. Corporate Tax Structure

13.2.10. Investments

13.2.11. Major Companies

13.3. Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

13.4. Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

13.5. Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

13.6. Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market: Country Analysis

13.7. Russia Market

13.8. Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

13.9. Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

13.10. Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

14. North America Market

14.1. Summary

14.2. North America Market Overview

14.2.1. Region Information

14.2.2. Market Information

14.2.3. Background Information

14.2.4. Government Initiatives

14.2.5. Regulations

14.2.6. Regulatory Bodies

14.2.7. Major Associations

14.2.8. Taxes Levied

14.2.9. Corporate tax structure

14.2.10. Investments

14.2.11. Major Companies

14.3. North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

14.4. North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

14.5. North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

14.6. North America Adalimumab, Infliximab and Etanercept Biosimilars Market: Country Analysis

14.7. USA Market

14.8. Summary

14.9. USA Market Overview

14.9.1. Country Information

14.9.2. Market Information

14.9.3. Background Information

14.9.4. Government Initiatives

14.9.5. Regulations

14.9.6. Regulatory Bodies

14.9.7. Major Associations

14.9.8. Taxes Levied

14.9.9. Corporate Tax Structure

14.9.10. Investments

14.9.11. Major Companies

14.10. USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

14.11. USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

14.12. USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

15. South America Market

15.1. Summary

15.2. South America Market Overview

15.2.1. Region Information

15.2.2. Market Information

15.2.3. Background Information

15.2.4. Government Initiatives

15.2.5. Regulations

15.2.6. Regulatory Bodies

15.2.7. Major Associations

15.2.8. Taxes Levied

15.2.9. Corporate Tax Structure

15.2.10. Investments

15.2.11. Major Companies

15.3. South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

15.4. South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

15.5. South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

15.6. South America Adalimumab, Infliximab and Etanercept Biosimilars Market: Country Analysis

15.7. Brazil Market

15.8. Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

15.9. Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

15.10. Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

16. Middle East Market

16.1. Summary

16.2. Middle East Market Overview

16.2.1. Region Information

16.2.2. Market Information

16.2.3. Background Information

16.2.4. Government Initiatives

16.2.5. Regulations

16.2.6. Regulatory Bodies

16.2.7. Major Associations

16.2.8. Taxes Levied

16.2.9. Corporate Tax Structure

16.2.10. Investments

16.2.11. Major Companies

16.3. Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

16.4. Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

16.5. Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

17. Africa Market

17.1. Summary

17.2. Africa Market Overview

17.2.1. Region Information

17.2.2. Market Information

17.2.3. Background Information

17.2.4. Government Initiatives

17.2.5. Regulations

17.2.6. Regulatory Bodies

17.2.7. Major Associations

17.2.8. Taxes Levied

17.2.9. Corporate Tax Structure

17.2.10. Investments

17.2.11. Major Companies

17.3. Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

17.4. Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

17.5. Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

18. Competitive Landscape And Company Profiles

19. Company Profiles

19.1. Biogen

19.1.1. Company Overview

19.1.2. Products And Services.

19.1.3. Business Strategy

19.1.4. Financial Overview

19.2. Novartis AG (Sandoz)

19.2.1. Company Overview

19.2.2. Products And Services.

19.2.3. Business Strategy

19.2.4. Financial Overview

19.3. Pfizer Inc.

19.3.1. Company Overview

19.3.2. Products And Services

19.3.3. Business Strategy

19.3.4. Financial Overview

19.4. Amgen Inc

19.4.1. Company Overview

19.4.2. Products And Services.

19.4.3. Business Strategy

19.4.4. Financial Overview

19.5. Celltrion

19.5.1. Company Overview

19.5.2. Products And Services

19.5.3. Business Strategy

19.5.4. Financial Overview

20. Pipeline Analysis

21. Key Mergers And Acquisitions In The Market

21.1. Fresenius Kabi Acquired mAbxience

21.2. Biocon Biologics to Acquire Viatris Biosimilars Business

21.3. Celltrion Acquired Assets Of Takeda Pharmaceuticals

21.4. Amgen Acquired Japanese JV with Astellas

21.5. True North Acquired Stake In Biocon Biologics Ltd.

21.6. Biocon Acquired Research and Development (R&D) Facility from Pfizer Healthcare India

21.7. Ligand Pharmaceuticals Acquired Pfenex

21.8. PAG Acquired Hisun BioRay Bio-pharmaceutical Co., Ltd.

21.9. Samsung Bioepis Enters Into An Agreement With C-Bridge Capital

21.10. Fuji Pharma Co., Ltd. Acquired Stake In Alvotech

21.11. Biocon Merged With Sandoz

22. Global Adalimumab, Infliximab and Etanercept Biosimilars Market Opportunities And Strategies

22.1. Global Adalimumab, Infliximab and Etanercept Biosimilars Market In 2026 – Countries Offering Most New Opportunities

22.2. Global Adalimumab, Infliximab and Etanercept Biosimilars Market In 2026 – Segments Offering Most New Opportunities

22.3. Global Adalimumab, Infliximab And Etanercept Biosimilars Market In 2026 – Growth Strategies

22.3.1. Market Trend Based Strategies

22.3.2. Competitor Strategies

23. Adalimumab, Infliximab and Etanercept Biosimilars Market, Conclusions And Recommendations

23.1. Conclusions

23.2. Recommendations

23.2.1. Product

23.2.2. Place

23.2.3. Price

23.2.4. Promotion

23.2.5. People

24. Appendix

24.1. Market Data Sources

24.2. Research Methodology

24.3. Currencies

24.4. The Business Research Company

24.5. Copyright and Disclaimer

List Of Tables

Table 1: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million

Table 2: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Table 3: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, By Region, Historic and Forecast, 2016 – 2021, 2026F, 2031F, %

Table 4: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, By Region, Historic and Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 5: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, By Country, Historic and Forecast, 2016 – 2021, 2026F, 2031F, %

Table 6: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, By Country, Historic and Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 7: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 8: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 9: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 10: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 11: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 12: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 13: Asia-Pacific Population By Age Group, By Country, 2016-2026, Thousands

Table 14: Asia-Pacific GDP Per Capita, By Country, 2016-2021, $

Table 15: Asia-Pacific Public Healthcare Expenditure, 2015-2020, $ Billion

Table 16: Asia-Pacific Private Healthcare Expenditure, 2015-2020, $ Billion

Table 17: Asia-Pacific, Healthcare Services Market Size, By Country, 2016-2026, $ Billion

Table 18: Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million

Table 19: Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Table 20: Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 21: Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 22: China Population By Age Group, 2016-2026, Thousands

Table 23: China GDP Per Capita, 2016-2021, $

Table 24: China Public Healthcare Expenditure And Private Healthcare Expenditure, 2015-2020, $ Billion

Table 25: China Healthcare Services Market Size, By Country, 2016-2026, $ Billion

Table 26: China Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million

Table 27: China Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Table 28: China Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 29: China Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 30: India Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million

Table 31: India Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Table 32: India Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 33: India Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 34: Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million

Table 35: Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Table 36: Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 37: Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 38: Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million

Table 39: Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Table 40: Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 41: Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 42: Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million

Table 43: Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Table 44: Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 45: Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 46: South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million

Table 47: South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Table 48: South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 49: South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 50: Western Europe Population By Age Group, By Country, 2016-2026, Thousands

Table 51: Western Europe GDP Per Capita, By Country, 2016-2021, $

Table 52: Western Europe Public Healthcare Expenditure, 2015-2020, $ Billion

Table 53: Western Europe Private Healthcare Expenditure, 2015-2020, $ Billion

Table 54: Western Europe Healthcare Services Market Size, By Country, 2016-2026, $ Billion

Table 55: Western Smart Europe Washing Machines Market, Historic, 2016 – 2021, $ Million

Table 56: Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Table 57: Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 58: Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 59: UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million

Table 60: UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Table 61: UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 62: UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 63: Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million

Table 64: Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Table 65: Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 66: Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 67: France Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million

Table 68: France Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Table 69: France Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 70: France Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 71: Eastern Europe Population By Age Group, By Country, 2016-2026, Thousands

Table 72: Eastern Europe GDP Per Capita, By Country, 2016-2021, $

Table 73: Eastern Europe Public Healthcare Expenditure, 2015-2020, $ Billion

Table 74: Eastern Europe Private Healthcare Expenditure, 2015-2020, $ Billion

Table 75: Eastern Europe Healthcare Services Market Size, By Country, 2016-2026, $ Billion

Table 76: Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million

Table 77: Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Table 78: Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 79: Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 80: Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million

Table 81: Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Table 82: Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 83: Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 84: North America Population By Age Group, By Country, 2016-2026, Thousands

Table 85: North America GDP Per Capita, By Country, 2016-2021, $

Table 86: North America Public Healthcare Expenditure, 2015-2020, $ Billion

Table 87: North America Private Healthcare Expenditure, 2015-2020, $ Billion

Table 88: North America Healthcare Services Market Size, By Country, 2016-2026, $ Billion

Table 89: North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million

Table 90: North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Table 91: North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 92: North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 93: USA Population By Age Group, 2016-2026, Thousands

Table 94: USA GDP Per Capita, 2016-2021, $

Table 95: USA Public Healthcare Expenditure And Private Healthcare Expenditure, 2015-2020, $ Billion

Table 96: USA Healthcare Services Market Size, By Country, 2016-2026, $ Billion

Table 97: USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million

Table 98: USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Table 99: USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 100: USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 101: South America Population By Age Group, By Country, 2016-2026, Thousands

Table 102: South America GDP Per Capita, By Country, 2016-2021, $

Table 103: South America Public Healthcare Expenditure, 2015-2020, $ Billion

Table 104: South America Private Healthcare Expenditure, 2015-2020, $ Billion

Table 105: South America Healthcare Services Market Size, By Country, 2016-2026, $ Billion

Table 106: South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million

Table 107: South America Washing Machines Market, Forecast, 2021 – 2026, 2031F, $ Million

Table 108: South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 109: South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 110: Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million

Table 111: Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Table 112: Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 113: Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 114: Middle East Population By Age Group, By Country, 2016-2026, Thousands

Table 115: Middle East GDP Per Capita, By Country, 2016-2021, $

Table 116: Middle East Public Healthcare Expenditure, 2015-2020, $ Billion

Table 117: Middle East Private Healthcare Expenditure, 2015-2020, $ Billion

Table 118: Middle East Healthcare Services Market Size, 2016-2026, $ Billion

Table 119: Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million

Table 120: Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Table 121: Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 122: Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 123: Africa Population By Age Group, By Country, 2016-2026, Thousands

Table 124: Africa GDP Per Capita, By Country, 2016-2021, $

Table 125: Africa Public Healthcare Expenditure, 2015-2020, $ Billion

Table 126: Africa Private Healthcare Expenditure, 2015-2020, $ Billion

Table 127: Africa Healthcare Services Market Size, 2016-2026, $ Billion

Table 128: Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million

Table 129: Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Table 130: Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 131: Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 132: Global Adalimumab, Infliximab And Etanercept Biosimilars Market, Key Competitor Estimated Market Shares, 2021, Percentage (%)

Table 133: Biogen – Financial Performance, 2017– 2021, $ Billion

Table 134 Novartis – Financial Performance, 2017– 2021, $ Billion

Table 135: Pfizer – Financial Performance, 2017– 2021, $ Billion

Table 136 Amgen – Financial Performance, 2017– 2021, $ Billion

Table 137: Celltrion – Financial Performance, 2017– 2021, $ Billion

Table 138: Global Adalimumab, Infliximab and Etanercept Biosimilars Market Size Gain ($ Million), 2021 – 2026, By Country

Table 139: Global Adalimumab, Infliximab and Etanercept Biosimilars Market Size Gain ($ Million), Segmentation By Product, 2021 – 2026

Table 140: Global Adalimumab, Infliximab and Etanercept Biosimilars Market Size Gain ($ Million), Segmentation By Application, 2021 – 2026

Table 141: Global Adalimumab, Infliximab and Etanercept Biosimilars Market Size Gain ($ Million), Segmentation By Distribution Channel, 2021 – 2026

Table 142: Adalimumab, Infliximab and Etanercept Biosimilars Market Data Sources

List Of Figures

Figure 1: Geographic Regions Covered

Figure 2: Global Adalimumab, Infliximab And Etanercept Biosimilars Market Segmentation By Product

Figure 3: Global Adalimumab, Infliximab And Etanercept Biosimilars Market Segmentation By Application

Figure 4: Global Adalimumab, Infliximab And Etanercept Biosimilars Market Segmentation By Distribution Channel

Figure 5: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 6: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 7: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, By Region, Historic and Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 8: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, By Country, Historic and Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 9: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 10: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 11: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 12: Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 13: Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 14: Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 15: China Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 16: China Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 17: China Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 18: India Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 19: India Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 20: India Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 21: Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 22: Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 23: Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 24: Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 25: Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 26: Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 27: Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 28: Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 29: Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 30: South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 31: South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 32: South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 33: Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 34: Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 35: Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 36: UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 37: UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 38: UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 39: Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 40: Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 41: Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 42: France Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 43: France Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 44: France Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 45: Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 46: Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 47: Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 48: Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 49: Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 50: Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 51: North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 52: North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 53: North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 54: USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 55: USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 56: USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 57: South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 58: South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 59: South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 60: Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 61: Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 62: Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 63: Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 64: Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 65: Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 66: Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 67: Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 68: Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 69: Global Adalimumab, Infliximab And Etanercept Biosimilars Market, Key Competitor Estimated Market Shares, 2021, Percentage (%)

Figure 70: Biogen – Financial Performance, $ Billion

Figure 71: Novartis – Financial Performance, 2017– 2021, $ Billion

Figure 72: Pfizer – Financial Performance, 2017– 2021, $ Billion

Figure 73: Amgen – Financial Performance, 2017– 2021, $ Billion

Figure 74: Celltrion – Financial Performance, 2017– 2021, $ Billion

The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the hematology drugs market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the GI drugs market research report 2022 with industry size, share, segments and market growth

CAR-T Therapy Market 2021 - By Target Antigen (CD19, CD22, BCMA), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma), And By Region, Opportunities And Strategies – Global Forecast To 2030

View Report

Central Nervous System Drugs Market 2021 - By Type (Multiple Sclerosis (MS), Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, Other CNS Drugs), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Administration (Oral, Intravenous, Intranasal/ Inhalation), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Over-The-Counter Drugs, Prescription-Based Drugs), And By Region, Opportunities And Strategies – Global Forecast To 2030

View Report

Oral Biologics & Biosimilar Drugs Global Market Report 2024 – By Therapy (Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors), By Disease (Asthma, Crohn's Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis and Others), By Molecule Type (Vaccines, Proteins & Peptides, Monoclonal Antibodies, Other Molecule Types), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Cellular Immunotherapy Global Market Report 2024 – By Therapy (Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy), By Primary Indication (B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma, Other Primary Indications), By Application (Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumor, Lung Cancer, Other Applications ) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Oligonucleotide Therapy Global Market Report 2024 – By Type (Antisense Oligonucleotide, Aptamer, Other Types), By Application (Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, Kidney Diseases, Other End-User), By End User (Hospitals, Research Institutes) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Cell Therapy Global Market Report 2024 – By Technique (Stem Cell Therapy, Cell Vaccine, Adoptive Cell Transfer (ACT), Fibroblast Cell Therapy, Chondrocyte Cell Therapy), By Therapy Type (Allogeneic Therapies, Autologous Therapies), By Application (Oncology, Cardiovascular Disease (CVD), Orthopedic, Wound Healing, Other Applications) – Market Size, Trends, And Global Forecast 2024-2033

View Report

HIV Drugs Global Market Report 2024 – By Type (Nucleoside Reverse Transcriptase Inhibitors (NRT’s), Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s), Protease Inhibitors, Integrase strand transfer inhibitors (INSTIs), Other Types), By Administration (Oral, Parenteral), By Application (Hospital Pharmacies, Retail Pharmacies, Other Applications) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Antidepressants Global Market Report 2024 – By Product (Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-norepinephrine Reuptake Inhibitor (SNRI), Tricyclic Antidepressant (TCA), Monoamine Oxidase Inhibitor (MAOI)), By Drug Class (Monoamine Oxidase Inhibitors, Serotonin Antagonist And Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Tricyclic Antidepressants), By Depressive Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Adalimumab, Infliximab And Etanercept Biosimilars Global Market Opportunities And Strategies To 2031

Adalimumab, Infliximab And Etanercept Biosimilars Global Market Opportunities And Strategies To 2031

Adalimumab, Infliximab And Etanercept Biosimilars Market Definition

Adalimumab, Infliximab And Etanercept Biosimilars Market Size

Adalimumab, Infliximab And Etanercept Biosimilars Market Drivers

Adalimumab, Infliximab And Etanercept Biosimilars Market Restraints

Adalimumab, Infliximab And Etanercept Biosimilars Market Trends

Opportunities And Recommendations In The Adalimumab, Infliximab And Etanercept Biosimilars Market

Adalimumab, Infliximab And Etanercept Biosimilars Market Segmentation

Adalimumab, Infliximab And Etanercept Biosimilars Market Competitive Landscape

Major Competitors are:

Other Competitors Include:

Table Of Contents

List Of Tables

List Of Figures

The Plasma Fractionation Market Share, Market Size, And Growth Rate 2022

The Biosimilar Therapeutic Peptides Market Share, Market Size, And Growth Rate 2022

Global Anticoagulants Market 2022 – Market Opportunities And Strategies

What Is The Compression Therapy Market Overview In 2022?

The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the hematology drugs market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the GI drugs market research report 2022 with industry size, share, segments and market growth

CAR-T Therapy Market 2021 - By Target Antigen (CD19, CD22, BCMA), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma), And By Region, Opportunities And Strategies – Global Forecast To 2030

Frequently Asked Questions